{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"5.4","value":"4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines defined as the time from the date of first dose of study drug to first documented objective progressive disease (PD) or death from any cause. PD is defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed 500 mg/m\\^2 administered by IV infusion followed by cisplatin 75 mg/m\\^2 administered by IV infusion both given on Day 1 of each 21 day cycle. Cetuximab 400 mg/m\\^2 administered by IV infusion initially as a loading dose in Week 1, subsequent weeks cetuximab 250 mg/m\\^2 administered by IV infusion once per week for a maximum of six 21 day cycles. At the discretion of the investigator participants who completed at least 4 cycles of triplet combination therapy could continue to receive pemetrexed plus cetuximab in the maintenance setting or as a monotherapy of pemetrexed or cetuximab alone in the absence of PD, unacceptable toxicity or any other withdrawal criterion up to 19 months. Participants also received Folic Acid and Vitamin B12 as standard of care dietary supplements.","id":"OG000","title":"Pemetrexed Cisplatin Cetuximab"}],"paramType":"MEDIAN","populationDescription":"Protocol Qualified (PQ) Population: all randomized and treated participants","reportingStatus":"POSTED","timeFrame":"Baseline to date of PD or death up to 18.7 months","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}